A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer (NCT06038578)
A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- City of Hope — Duarte, California
- City of Hope at Orange County Lennar Foundation Cancer Center — Irvine, California
- University of California, Los Angeles — Santa Monica, California
- Texas Oncology Arlington North — Arlington, Texas
- Texas Oncology Bedford — Bedford, Texas
- Texas Oncology Dallas Methodist — Dallas, Texas
- Texas Oncology Dallas Medical City — Dallas, Texas
- Texas Oncology Dallas Presbyterian — Dallas, Texas
- Texas Oncology Methodist Charlton Cancer Center — Dallas, Texas
- Texas Oncology-Sammons Cancer Center — Dallas, Texas
- Texas Oncology Fort Worth Cancer Center — Fort Worth, Texas
- Texas Oncology Grapevine — Grapevine, Texas
- Texas Oncology Plano East — Plano, Texas
- Texas Oncology Plano West — Plano, Texas
- Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center — Yokohama, Kanagawa
- Saitama Prefectural Hospital Organization Saitama Cancer Center — Shinden, Saitama
- Shizuoka Cancer Center — Nagaizumi-cho, Shizuoka
- National Cancer Center Hospital — Chūōku,
- Osaka International Cancer Institute — Chūōku,
- National Cancer Center Hospital East — Kashiwa,
- The Cancer Institute Hospital of JFCR — Kōtoku,
- Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do
- Chonnam National University Hwasun Hospital — Hwasun, Jeollanam-do
- Kyungpook National University Chilgok Hospital — Daegu,
- Severance Hospital — Seoul,
📞 Contact the Study Coordinator
Phone: +81 467-32-9948
Email: npdd-clinical.toray.mb@mail.toray
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastric Adenocarcinoma
- Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer — Tucson, Arizona
- Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors — Scottsdale, Arizona
- Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma — Philadelphia, Pennsylvania
- Magnetic Sentinel Lymph Node Mapping in Gastric Cancer — Houston, Texas
- GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer — Chicago, Illinois
- A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology — Houston, Texas
Explore by condition: All Gastric Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.